Portage Biotech, Inc.
- Country
- 🇨🇦Canada
- Ownership
- Public
- Established
- 1973-01-01
- Employees
- 7
- Market Cap
- $6.7M
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
- Conditions
- Renal Cell CancerCastrate Resistant Prostate CancerNon Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaColorectal Cancer (CRC)Endometrial CancerOvarian Cancer
- Interventions
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Portage Biotech
- Target Recruit Count
- 90
- Registration Number
- NCT04969315
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
News
PORT-7 Shows Over 90% Tumor Reduction in Mesothelioma Preclinical Studies, First-In-Human Trial Planned
Portage Biotech's selective Adenosine A2B receptor inhibitor PORT-7 demonstrated significant single-agent activity and over 90% tumor growth inhibition when combined with anti-PD1 antibody in murine mesothelioma models.
Adenosine Antagonists Show Promise in Clinical Trials for Cancer and COPD
• Adenosine antagonists are under investigation for novel therapeutic applications in neurodegenerative diseases, oncology, and cardiovascular disorders. • Several companies, including Arcus Biosciences and Corvus Pharmaceuticals, are advancing adenosine antagonists through clinical trials to improve treatment landscapes. • Clinical trials are evaluating drugs like etrumadenant, ciforadenant and PBF-680 in various phases for conditions like colorectal cancer, prostate cancer and COPD.